

Policy Title:	Oncology Medication Policy		
Policy Number:	000643	Department:	PHA
Effective Date:	02/13/2019		
Review Date:			
Revision Date:			

Purpose:

To ensure Neighborhood Health Plan of Rhode Island (NHPRI) covers oncology medications that are clinically appropriate, cost effective, and supported by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium as indicated by a Category 1 or 2A for quality of evidence and level of consensus.

Scope:

Medicaid, Exchange*, Medicare MMP*

*(policy only applies to medically administered drugs for these lines of business)

Policy Statement:

The New to Market Policy will not apply to oncology medications. Oncology medications will be available through this policy when the medications become available for Medicaid and medically administered drugs for MMP and Exchange. (Note the retail pharmacy formulary for MMP and Exchange is managed by NHP's PBM).

In the absence of a specific policy, these agents will be covered by NHPRI as long as NCCN guidelines are followed. Specifically

- Drug is being used for a medically accepted indication according to the NCCN Drugs and Biologics Compendium as indicated by a Category 1 or 2A
- NHPRI will periodically require clinical notes to audit for compliance
- Payments will be retracted for non-compliance.

For medications used outside of these guidelines, providers should request authorization from the plan prior to use.

Medications without a specific j-code, requiring use of an unclassified j-code, require authorization from the plan for payment.

The Pharmacy department will evaluate new to market oncology drugs and significant changes in the use of the oncology drugs and where appropriate may bring a particular oncology agent to the Pharmacy & Therapeutics committee for review and specific management criteria.

NHPRI may require the use of a biosimilar or adjust rates where there are multiple agents available.

